Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Exec appointment
confidence 95%
filed 2026-06-30
EX-99.1
The exhibit announces the completion of a planned CEO transition with two key executive appointments effective July 1, 2026: Ender Özgün as Chief Executive Officer of Hepsiburada with overall company responsibility, and Hakan Karadoğan as CEO of the Delivery business. While Nilhan Gökçetekin's departure is also disclosed, the principal disclosed action is the appointment of new leadership to critical executive roles, making this an exec_appointment event. This is material as it represents a significant change in the company's leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-30
Item 5.02
The filing discloses the appointment of Charlie Cole as Chief Executive Officer and Board member effective July 13, 2026, which is the principal action. While Andrew McLean's departure as CEO and Board member is also disclosed, the salient event centers on the new CEO appointment with detailed compensation terms ($1.1M base, $550K signing bonus, $2.5M in equity grants, and $3.025M+ annual LTI). This is a material executive leadership change for the registrant.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
The filing discloses the appointment of Margaret M. Weichert to the Board of Directors of Primis Financial Corp. and Primis Bank, effective June 25, 2026, at the recommendation of the Corporate Governance Committee. The prose centers on her election and appointment to the boards and the Corporate Governance Committee, with detailed background on her qualifications. This is a clear executive appointment event material to investors assessing board composition and governance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-06-30
EX-99.1
The announcement discloses the Board's appointment of Søren Steenberg Jensen, EVP Head of Asset Management, as the successor to CEO Mikael Skov, effective 1 September 2026. While the disclosure also mentions Skov's departure, the principal disclosed action is the appointment of a new CEO to lead the company. This is a material executive succession at the top of the organization affecting investor assessment of leadership continuity and strategy execution.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-30
Item 5.02
The filing discloses the appointment of Joseph Manhede as Principal Accounting Officer effective July 8, 2026, following the resignation of John Militello. While both a departure and appointment occur, the principal disclosed action centers on the appointment of a named executive to a principal officer role (Principal Accounting Officer), making exec_appointment the most salient classification. The appointment of a Principal Accounting Officer is material to investors as it affects financial reporting oversight and internal controls.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-30
Item 5.02
The Company appointed three new directors—Yongchen Lu, Monica Roma Wilson, and Eduardo Agustin Ojea Quintana—effective June 24, 2026, expanding the board from two to five members and establishing the governance structure of the newly public SPAC.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 85%
filed 2026-06-30
The 6-K discloses the appointment of two new independent directors (Ms. Tian Ke and Mr. Lin Junteng) effective June 30, 2026, along with the simultaneous resignation of two existing directors (CHAN KA MAN and LAI HO YIN). While both departures and appointments occur, the principal disclosed action is the appointment of the new directors to fill those vacancies, making exec_appointment the primary classification. The reconstitution of board committees reflects the structural consequence of these director changes. Board composition changes are material to investors assessing governance and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
Z Squared Inc. appointed Jeffery Harris as Chief Technology Officer, effective June 24, 2026. Harris, founder and CTO of Paradox Data LLC (which the Company is acquiring), brings expertise in AI infrastructure, data center design, and immersion cooling technology. The appointment includes compensatory arrangements of $225,000 base salary, $675,000 annual bonus RSUs, and a stock option grant.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-30
EX-99
The exhibit discloses the Board's approval of two executive appointments: Mr. Puneet Sharma as Chief Financial Officer-Designate (effective September 1, 2026, becoming CFO on December 1, 2026) and Mr. Jigar Shah as General Counsel-Designate (effective August 20, 2026, becoming General Counsel on October 1, 2026). Both will be Senior Management Personnel, and Sharma will become a Key Managerial Person under Indian law. These are material C-suite appointments at a major bank that would affect investor assessment of management quality and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
Chae Lee was appointed as Chief Executive Officer and director of Magnachip Semiconductor, effective July 1, 2026. Camillo Martino transitioned from Interim CEO to Chairman. The appointment represents a significant leadership change at the company level.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-30
Item 5.02
The filing discloses the appointment of two new directors (Go Jin Young and Han Eui Seok) to the Board, effective June 30, 2026, following an increase in board size from five to six directors. While Ham Jung Kyu's resignation is also mentioned, the principal disclosed action centers on the two director appointments and the formation of a Compensation Committee with Han Eui Seok as Chair. This is a material governance event affecting board composition and committee structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 90%
filed 2026-06-30
Item 5.02
ALX Oncology appointed Scott Garland as Chairman of the Board (effective June 29, 2026) and Michael Listgarten as General Counsel (effective immediately), representing a significant governance transition. Corey Goodman, co-founder, stepped down as Chairman after more than a decade of leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
The filing discloses the appointment of Cynthia T. Jamison to Sunbelt Rentals' Board of Directors, effective August 1, 2026, along with her appointment to the Audit Committee. The principal disclosed action is a person taking a governance role. While the Board was expanded from eight to nine directors, the core event is the election and appointment of Ms. Jamison, a director with extensive board and executive leadership experience across major public companies (Darden, Advance Auto Parts, IFF) and financial expertise as a former CFO and CPA.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-30
The 6-K announces the appointment of four individuals—Mr. Xuan He, Ms. Xinyi Wei, Ms. Zhen Liao, and Ms. Yiwen Zhang—as executive directors of the Board, effective June 30, 2026. Mr. He also serves as chief financial officer. This is a material governance event involving the appointment of multiple senior officers to the board, expanding it from five to nine members with six executive directors and three independent directors.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-30
The 6-K discloses the appointment of Chung Wai Wong as a director and member of three board committees (Nominating and Corporate Governance, Audit, and Compensation) effective June 30, 2026. The filing provides her biographical information, independence determination under Nasdaq rules, and compensation terms ($12,000 annually). This is a clear executive appointment to the board with material governance implications.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
Thomas D. Hennessy was appointed to the SPAC Board on June 25, 2026, pursuant to a Transfer Agreement, bringing extensive SPAC leadership and M&A expertise to the company's governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
The filing discloses the appointment of Karl Olsoni to the Board of Directors and the Audit Committee, effective June 30, 2026. While the disclosure also includes compensatory terms (annual cash retainer of $150,000 and annual stock award of $150,000), the principal action is the appointment itself. Board appointments are material to investors as they affect governance and oversight structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
The filing discloses the appointment of Allen C. Harper as Interim Chief Executive Officer and Principal Executive Officer of Rocky Mountain Chocolate Factory, effective immediately on June 30, 2026, for a 180-day term. This is a material executive appointment to the principal executive officer role, disclosed under Item 8.01 (Other Events) with supporting press release. The appointment of a new CEO is material to investors assessing the registrant's leadership and strategic direction.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-06-30
The 6-K discloses the appointment of Frank Zheng as Chief Executive Officer (effective June 30, 2026), Chang-Wei Chiu as Chairman and Compensation Committee Chair (effective June 30, 2026), and Tokihiko Shimizu as an independent director (effective June 30, 2026). While the filing also mentions the departures of Moore Xin Jin and Björn Schmidtke, the principal disclosed action is the appointment of new leadership, making this an exec_appointment event. The CEO transition is material to a reasonable investor's assessment of the company.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-30
EX-99.1
The exhibit announces the appointment of Robin Hoksnes Karlsen as an executive director of 707 Cayman Holdings Limited by the board of directors, with entry into a standard director agreement. This is a clear executive appointment disclosure. The appointment is material because it involves a new executive director joining the board with stated expertise in real estate, digital assets, and blockchain technologies that the company explicitly identifies as relevant to its strategic direction in "AI-powered blockchain-enabled supply-chain technologies."
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
The filing discloses under Item 5.02 the appointment of two new directors to the Board effective June 21, 2026: Ruoxin (Skyler) Wang and Zhang Zhixiang. The prose explicitly states "the Board of Directors...appointed Ruoxin (Skyler) Wang and Zhang Zhixiang as members of the Board, and they accepted their appointments as directors." This is a clear executive appointment event, material to investors as board composition affects governance and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-30
Item 5.02
The filing discloses the election of Paul W. Burkett as a director effective July 1, 2026, with appointment to three Board committees (Audit, Corporate Governance and Nominating, and Transaction Committee). While the section also mentions Michael J. Wartell's resignation, the principal disclosed action centers on the appointment of a new director with significant committee responsibilities. The appointment of an independent director to key governance committees is material to investors' assessment of board composition and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-30
The filing discloses both the retirement of interim CFO Jeffrey Church (effective July 1, 2026) and the appointment of Josh Blacher as the new interim Chief Financial Officer under a master services agreement with Danforth Health, Inc. While both events occur, the principal disclosed action centers on the appointment of Blacher to the CFO role, with detailed biographical information and compensation terms ($475/hour). The departure of Church is secondary context. This is material as CFO changes affect investor assessment of financial reporting and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-30
The filing discloses the appointment of Andrew Cordell Schaap as a board member effective June 29, 2026, with concurrent appointment to the Audit Committee and Related Party Transactions Committee. While the disclosure also includes a compensatory arrangement (a 200,000-share restricted stock award), the principal disclosed action is the appointment itself. The board expansion from seven to eight members and committee assignments are the core events, making this an exec_appointment rather than exec_compensation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
The filing discloses the appointment of Tomas J. Philipson, Ph.D. to the Board of Directors effective June 26, 2026, along with his concurrent appointment to the Audit Committee and Compensation Committee. While the disclosure also includes compensatory arrangements (equity options totaling 536,428 shares), the principal disclosed action is the appointment of a director with significant government and healthcare economics experience to the board and key committees. This is a material governance event affecting board composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
The filing discloses the appointment of Mark Capone as a Class II director effective July 1, 2026, and his concurrent appointment to the Compensation Committee. The principal disclosed action is a person taking a role on the Board and a Board committee. While the filing also details compensatory arrangements (equity grants and cash compensation), the core event is the appointment itself, making exec_appointment the most salient classification. The appointment of an experienced healthcare executive with 40+ years in diagnostics and prior CEO experience at Myriad Genetics is material to investors assessing the company's governance and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-30
Item 5.02
Nicholas T. Meserve, currently a Managing Director, will transition to the role of CEO in Q4 2026, while incumbent Dwayne L. Hyzak transitions to Executive Chairman. This represents a material executive succession and change in leadership roles.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
Perrigo appointed two independent directors, Salman Amin and Omer Gajial, to its Board of Directors effective June 30, 2026, increasing board size from 8 to 10 members. Both appointees bring substantial executive experience in consumer products, retail, and digital transformation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
Guus Franke was appointed Chief Executive Officer by the Board on June 29, 2026, while continuing as Executive Chairman, representing a material executive leadership transition. Jeffrey Jagid transitioned from CEO to President. The appointment reflects the company's strategic evolution as it rebrands to Circle8 Group, Inc.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
Amanda Cole was appointed as Vice President and Chief Human Resources Officer effective July 21, 2026, reporting to the CEO and overseeing global HR, communications, and EHSQ functions. The appointment also coincided with the retirement of Judith Bacchus from the same role.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
Three new directors—Becky Fallon, Sean Michael Deegan, and Robert Labbe—were appointed to the board effective June 24, 2026, in connection with the company's IPO registration statement effectiveness, with specified committee assignments and independence qualifications.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-06-30
Item 5.02
Xeris Biopharma appointed Dr. Nerissa Kreher to its Board of Directors effective July 1, 2026, expanding the Board from seven to eight members. Concurrent with this appointment, John Shannon was appointed Chairperson and Marla Persky transitioned to Lead Independent Director. Dr. Kreher received initial equity compensation of approximately $450,000.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 82%
filed 2026-06-30
Item 5.02
On June 26–29, 2026, Graphene & Solar Technologies appointed Daniel Kennedy and Theresa Jester as directors, appointed Paul Saffron as Company Secretary, and saw the resignation of Charles Wantrup from the Board and Kristine Woo as Interim Company Secretary. The principal disclosed actions center on the appointments of new directors and a new officer, representing material governance and leadership changes.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 93%
filed 2026-06-30
Item 5.02
Dr. William Grieco was appointed as Chief Executive Officer and Class I director of Innventure, effective October 1, 2026, following a comprehensive board succession planning process. The appointment includes compensation terms of $550,000 base salary, $1M RSU grant, and $1.5M annual equity grant. The transition was announced via press release and represents a material leadership change for the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
The filing discloses the appointment of Jack Viellieu as Chief Operating Officer of Blue Owl Digital Infrastructure Trust, effective June 30, 2026. While the section also mentions Bradley Berkley's resignation as COO, the principal disclosed action centers on the appointment of a new officer to a senior executive role. The detailed background on Mr. Viellieu's qualifications and experience, combined with the explicit statement that his selection was not pursuant to any arrangement, confirms this is an executive appointment disclosure. This is material as it involves a change in senior management responsible for operations.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
The Board of Directors elected Bertrand Loy and Kevin Wheeler as directors effective August 1, 2026, and appointed them to specific Board committees. This is a clear executive appointment disclosure under Item 5.02. Both appointees bring substantial public company CEO experience and relevant industrial manufacturing expertise, making their appointments material to investors' assessment of board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-29
Item 5.02
The filing discloses the appointment of Valeriy Kim as Chief Financial Officer effective June 25, 2026, succeeding Evgeny Ler. While the section also mentions Ler's departure and Kim's compensatory arrangements (base salary of $1,132,692, annual bonus of $1,000,000, and 15,000 shares annually), the principal disclosed action centers on the appointment of a new CFO. The appointment of a CFO is material to investors as it affects the registrant's financial leadership and governance structure.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-29
EX-99
The exhibit discloses the Board's approval of Mr. Rajiv Kumar's appointment as an Additional (Independent) Director effective June 30, 2026, and as Part-time Chairman (subject to RBI approval). This is a material executive appointment of a senior leadership position at a major financial institution, with detailed biographical information demonstrating his significant public-sector banking and financial-services reform credentials. The appointment directly affects governance and leadership structure.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-29
EX-99.1
Professor Duncan Murray Campbell was appointed as a director of MDJM Ltd. for a two-year term, intended to strengthen the company's professional capabilities in cultural governance and strategy.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-06-29
EX-99.2
María Consuelo Loureiro Vilarello (Chelo Loureiro) was appointed as Chief Knowledge Officer of MDJM Ltd. for an initial two-year term pursuant to an employment agreement, bringing industry credentials expected to impact the company's animation and cultural strategy.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
The Board appointed two new directors, David Endicott and Linnea Burman, effective June 29, 2026, increasing the Board size from nine to 11 members. Both appointments include full biographical details, independence determinations, and compensation arrangements.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
Jonathan Collins was appointed as Senior Vice President, Finance and Chief Financial Officer of Genesco, effective August 3, 2026, following a comprehensive search process. Collins brings 30+ years of financial leadership experience, including prior roles at Walmart and America's Car-Mart. The appointment includes a base salary of $550,000, target incentive of $412,500, and long-term incentive target of $825,000.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-29
EX-99.1
The exhibit announces the appointment of Dr. Srishti Gupta as Chief Executive Officer and Board member of NovaBridge Biosciences, effective July 1, 2026. While the announcement also discloses that Xi-Yong (Sean) Fu is stepping down as CEO, the principal disclosed action is Gupta's appointment to the CEO role. The disclosure emphasizes her extensive leadership experience across biopharmaceuticals and global health, and the Board's confidence in her ability to advance the company's pipeline and create shareholder value—a material change in executive leadership at a clinical-stage biopharmaceutical company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-06-29
Item 5.02
David Thompson was appointed Chief Financial Officer, Principal Accounting Officer, and Treasurer of CIM Group, Inc. (formerly CMFT) effective June 24, 2026, replacing Nathan D. DeBacker. Thompson received an equity award of 30,433.658 RSUs under the 2024 Manager Plan.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
Eric Hyllengren was appointed as Chief Financial Officer effective July 13, 2026, with responsibility for Principal Financial Officer and Principal Accounting Officer roles. The appointment includes compensatory arrangements consisting of a base salary of $490,000, a 40% target bonus, and an option grant of 1,650,000 shares.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
Fortune Brands Innovations appointed Jesse G. Singh as Chief Executive Officer and Class I Board member effective June 29, 2026, following a comprehensive search process. David V. Barry was appointed Executive Vice President and Chief Operating Officer, transitioning from his interim CEO role. Singh's compensation package includes a base salary of $1,100,000, a bonus target of 150%, and a long-term incentive award of $6,700,000.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-06-29
Item 5.02
A. Jayson Adair was appointed as Chief Executive Officer effective July 31, 2026, succeeding Jeffrey Liaw. This represents a significant leadership change at the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
The filing discloses the Board's unanimous election of Hilla Sferruzza as a director of Frontdoor, Inc., effective immediately, and her appointment to the Audit Committee. While the Item 5.02 section also describes her standard director compensation ($90,000 cash annually plus $180,000 in stock, plus $12,500 for Audit Committee service), the principal disclosed action is the appointment of a new director with significant finance and real estate expertise to the board and a key committee. This is a material governance event affecting board composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
David J. Johnson, Jr. was elected as a director of Domtar Corporation by resolution of its sole shareholder on June 26, 2026. The disclosure centers on the appointment of a new director and provides his qualifications and background. While the filing also mentions a consulting agreement with Gemsbok Partners LLC, the principal disclosed action is the election of a director, making this an exec_appointment event. Director appointments are material to investors as they affect board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
Three independent directors—Yi Hua, Xin Yue Jasmine Geffner, and Yuanmei Ma—were appointed effective June 25, 2026, in connection with the Company's Nasdaq listing and IPO closing, with Geffner designated as audit committee chair and qualified audit committee financial expert.
View raw filing on EDGAR →